Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
Jeffrey A. Cohen(Dartmouth Health), Ludwig Kappos(University Hospital of Basel), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Krzysztof Selmaj(University of Warmia and Mazury in Olsztyn), James K. Sheffield, Neil Minton, Gıancarlo Comı(Casa di Cura Columbus), Kartik Raghupathi, Hans‐Peter Hartung(The University of Sydney), Douglas L. Arnold(McGill University), Lawrence Steinman(Stanford University), Amit Bar‐Or(University of Pennsylvania), Vivian Huang, Eva Havrdová(Charles University), Bruce Cree(University of California, San Francisco)
Cited by 279
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k